Page last updated: 2024-12-08

org gc 94

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Org GC 94: serotonin antagonist; anti-migraine; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10363345
MeSH IDM0059811

Synonyms (18)

Synonym
1,3,,4,14b-tetrahydro-2,7-dimethyl-2h-dibenzo(b,f)pyrazino(1,2-d)(1,4)oxazepine maleate
1,3,4,14b-tetrahydro-2,7-dimethyl-2h-dibenzo(b,f)pyrazino(1,2-d)(1,4)-oxazepine maleate
org gc 94
einecs 254-804-3
gc 94
2h-dibenzo(b,f)pyrazino(1,2-d)(1,4)oxazepine, 1,3,4,14b-tetrahydro-2,7-dimethyl-, (z)-2-butenedioate (1:1)
org-gc-94
(-)-1,3,4,14b-tetrahydro-2,7-dimethyl-2h-dibenzo(b,f)pyrazino(1,2-d)(1,4)oxazepine maleate
einecs 286-831-1
85391-75-9
oc 94
mp745kp49d ,
unii-mp745kp49d
1,3,4,14b-tetrahydro-2,7-dimethyl-2h-dibenzo(b,f)pyrazino(1,2-d)(1,4)oxazepine maleate
gc-94
40132-36-3
(-)-1,3,4,14b-tetrahydro-2,7-dimethyl-2h-dibenzo[b,f]pyrazino[1,2-d][1,4]oxazepine maleate
Q27284157

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" As both the maximum contraction and the slope of the dose-response curves were reduced by increasing concentrations of Org GC 94, the antagonism of 5-HT did not involve competitive blockade of 5-HT receptors."( Interaction of a potential antimigraine drug (Org GC 94) with the vasomotor action of serotonin.
Hardebo, JE; Lamar, JC, 1979
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (66.67)18.7374
1990's2 (33.33)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (16.67%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]